Non-alcoholic Fatty Liver Diseases (NAFLD) Research This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Association between nonalcoholic fatty liver disease and left ventricular diastolic dysfunction: A 7-year retrospective cohort study of 3,380 adults using serial echocardiography
CONCLUSIONS: This study demonstrated that NAFLD was associated with an increased risk of LVDD in a large cohort. More severe forms of hepatic steatosis and/or significant liver fibrosis may increase the risk of developing LVDD.PMID:38608865 | DOI:10.1016/j.diabet.2024.101534 (Source: Diabetes and Metabolism)
Source: Diabetes and Metabolism - April 12, 2024 Category: Endocrinology Authors: Gyuri Kim Tae Yang Yu Jae Hwan Jee Ji Cheol Bae Mira Kang Jae Hyeon Kim Source Type: research

GSE260582 Mitochondrial ACSS1-K-635 acetylation mimic knock-in mice exhibit altered lipid metabolism, hepatic cell senescence, and acute non-alcoholic fatty liver [2ndSet_analysis]
Contributors : David Gius ; Guogang Xu ; Joseph Schell ; Nobuo Horikoshi ; Yidong Chen ; Zhao LaiSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusWe generated an ACSS1-acetylation (Ac) mimic mouse, where lysine 635 was mutated to glutamine (K635Q). Male Acss1K635Q/K635Q mice were smaller with higher metabolic rate and blood acetate, and decreased liver/serum ATP and lactate levels. After a 48-hour fast, Acss1K635Q/K635Q mice presented hypothermia and liver aberrations, including enlargement, discoloration, lipid droplet accumulation, and microsteatosis – consistent with nonalco...
Source: GEO: Gene Expression Omnibus - April 12, 2024 Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Mus musculus Source Type: research

GSE260581 Mitochondrial ACSS1-K-635 acetylation mimic knock-in mice exhibit altered lipid metabolism, hepatic cell senescence, and acute non-alcoholic fatty liver [1stSet_analysis]
Contributors : David Gius ; Guogang Xu ; Joseph Schell ; Nobuo Horikoshi ; Yidong Chen ; Zhao LaiSeries Type : Expression profiling by high throughput sequencingOrganism : Mus musculusWe generated an ACSS1-acetylation (Ac) mimic mouse, where lysine 635 was mutated to glutamine (K635Q). Male Acss1K635Q/K635Q mice were smaller with higher metabolic rate and blood acetate, and decreased liver/serum ATP and lactate levels. After a 48-hour fast, Acss1K635Q/K635Q mice presented hypothermia and liver aberrations, including enlargement, discoloration, lipid droplet accumulation, and microsteatosis – consistent with nonalco...
Source: GEO: Gene Expression Omnibus - April 12, 2024 Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Mus musculus Source Type: research

Optimal probiotic combinations for treating nonalcoholic fatty liver disease: A systematic review and network meta-analysis
Probiotic administration is a promising therapy for improving conditions in NAFLD patients. This network meta-analysis aimed to compare and estimate the relative effects of probiotic interventions and identify the optimal probiotic species for the treatment of NAFLD (Nonalcoholic fatty liver disease) patients. (Source: Clinical Nutrition)
Source: Clinical Nutrition - April 12, 2024 Category: Nutrition Authors: Yafang Yang, Ligang Yang, Jiale Wu, Jing Hu, Min Wan, Jindi Bie, Jiaxin Li, Da Pan, Guiju Sun, Chao Yang Source Type: research

Would Combination Be Better: Swimming Exercise and Intermittent Fasting Improve High-Fat Diet-Induced Nonalcoholic Fatty Liver Disease in Obese Rats via the miR-122-5p/SREBP-1c/CPT1A Pathway
(Source: Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy)
Source: Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy - April 11, 2024 Category: Endocrinology Tags: Diabetes, Metabolic Syndrome and Obesity Source Type: research

Establishment and validation of an adherence prediction system for lifestyle interventions in non-alcoholic fatty liver disease
CONCLUSION: The EDAS can reliably assess the adherence of patients with NAFLD to lifestyle interventions and have clinical application in this population.PMID:38596499 | PMC:PMC11000086 | DOI:10.3748/wjg.v30.i10.1393 (Source: World Journal of Gastroenterology)
Source: World Journal of Gastroenterology - April 10, 2024 Category: Gastroenterology Authors: Ming-Hui Zeng Qi-Yu Shi Liang Xu Yu-Qiang Mi Source Type: research

Establishment and validation of an adherence prediction system for lifestyle interventions in non-alcoholic fatty liver disease
CONCLUSION: The EDAS can reliably assess the adherence of patients with NAFLD to lifestyle interventions and have clinical application in this population.PMID:38596499 | PMC:PMC11000086 | DOI:10.3748/wjg.v30.i10.1393 (Source: World Journal of Gastroenterology : WJG)
Source: World Journal of Gastroenterology : WJG - April 10, 2024 Category: Gastroenterology Authors: Ming-Hui Zeng Qi-Yu Shi Liang Xu Yu-Qiang Mi Source Type: research

Deciphering the molecular pathways of saroglitazar: A dual PPAR α/γ agonist for managing metabolic NAFLD
Saroglitazar (SARO), a dual peroxisome proliferator activated receptor (PPAR)- α/γ agonist, has been used to treat metabolic diseases such as insulin resistance and diabetic dyslipidemia in patients with non-alcoholic fatty liver disease (NAFLD). SARO, administered at a dose of 4 mg/day, has been consistently studied in clinical trials with different time points ranging fr om 4 to 24 weeks with NAFLD patients. Due to its PPAR-γ agonistic action, SARO prevents adipose tissue-mediated fatty acid delivery to the liver by increasing insulin sensitivity and regulating adiponectin and leptin levels in adipose tissue. (Sou...
Source: Metabolism - Clinical and Experimental - April 10, 2024 Category: Biomedical Science Authors: Devaraj Ezhilarasan Tags: Review Source Type: research